Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:12 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis
NCT03598036 · Aurinia Pharmaceuticals Inc. · PHASE2 · terminated · last registry update 2021-09-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Low recruitment rate” | – | Registry record, Aurinia Pharmaceuticals Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PPP3CA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-03-21Phase 3 first posted: Aurinia Pharmaceuticals Inc., Voclosporin + Placebo Oral Capsule (NCT05288855)
- 2021-12-10Results posted on the registry: Aurinia Pharmaceuticals Inc., 0.05% Voclosporin Ophthalmic Solution (VOS) + 0.10% VOS (NCT04147650)
- 2021-07-08Results posted on the registry: Aurinia Pharmaceuticals Inc., Voclosporin Ophthalmic Solution + Restasis® (NCT03597139)
- 2021-06-16Results posted on the registry: Aurinia Pharmaceuticals Inc., Voclosporin + Placebo Oral Capsule (NCT03021499)
- 2021-05-18Results posted on the registry: Aurinia Pharmaceuticals Inc., Voclosporin High Dose + Voclosporin Low Dose (NCT02141672)
- 2021-03-19Results posted on the registry: Aurinia Pharmaceuticals Inc., voclosporin (NCT02949973)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision